Tag:

Eylea

Latest Headlines

Latest Headlines

Regeneron's Eylea bests Lucentis, Avastin in diabetic eye disease, NIH study finds

Regeneron and Bayer's Eylea has been racking up sales that have consistently topped analyst expectations since its U.S. rollout in late 2011. Now, new data may help it potentially top them in a market Novartis and Roche got to first.

Eylea gets yet another approval, this one in Japan

The approvals, and the sales, just keep piling up for Eylea, the blockbuster that Bayer shares with developer Regeneron. Just weeks after getting an important nod in Europe, it has won approval in Japan, the world's third largest market, for use in myopic choroidal neovascularization.

Regeneron nabs FDA 'breakthrough' tag for new Eylea use in diabetics

Plenty of drugmakers are chasing opportunity in diabetes. The fast-growing epidemic means new therapies are sorely needed. But dealing with diabetes directly isn't the only strategy. Regeneron figures it can score by treating some of the disease's long-term complications.

New use for Bayer's Eylea in EU gives it more market power against Novartis' Lucentis

The European Commission has approved Bayer's Eylea (aflibercept) for the treatment of diabetic macular edema, the most common cause of vision loss among people with diabetes.

Regeneron sales soar in Q2 on growing Eylea demand--what's new?

After a brief hiatus, Regeneron is back to steamrolling analysts' expectations. Tuesday, the drugmaker reported second-quarter results that topped Wall Street's projections, thanks once again to growing demand for macular degeneration treatment Eylea.

Bayer nabs new OKs for Eylea, Stivarga as top meds skate past forecasts

Bayer's drug business has been on a roll, thanks to some serious growth in its 5 newest products, including the clot-fighter Xarelto and the PAH med Adempas.

Bayer nabs new OKs for Eylea, Stivarga as top meds skate past forecasts

In March, Bayer CEO Marijn Dekkers boldly predicted that the company's 5 new drugs--including the blood thinner Xarelto and the macular degeneration treatment Eylea--would help his company achieve 8% annual sales growth through 2016. Judging from the company's second quarter results, Bayer is well on its way to making good on that goal.

Regeneron jumps into next-gen gene therapy tech with $640M eye drug deal

Regeneron is turning to gene therapy research to look for a successor to its blockbuster wet AMD drug Eylea.

With Big 5, Bayer aims for 8% annual pharma growth through 2016

The CEO of the German drugmaker is pinning some numbers on the medium term; the Big 5 will help Bayer aim for an average of 8% annual growth in its pharma unit through 2016, Marijn Dekkers said Wednesday.

Aiming for big growth in top 5 meds, Bayer will stake an extra $600M on marketing, R&D

Bayer knows what a good launch can do; with blood thinner Xarelto and eye drug Eylea, it's had a couple of the recent best. Thanks to that pair of hot-selling meds, the German pharma raised the sales forecast for its new products by €2 billion late last week--and it's raising its marketing budget along with it.